SCHEMBL31340012

SCHEMBL31340012

COc1ccc(-c2nc(NC(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)ncc2C)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ ADCY8 P40145 1/20 0.46
▸ ADCY1 Q08828 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SORT1 Q99523 1/20 0.44
▸ RUVBL1 Q9Y265 1/20 0.44
▸ LCK P06239 1/20 0.44
▸ BTK Q06187 1/20 0.44
▸ USP2 O75604 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ TRPV1 Q8NER1 1/20 0.43
▸ ADORA2A P29274 1/20 0.43
▸ ADORA1 P30542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31339978 0.88 BTK (0.48) SORT1LCKBTKTRPV1
SCHEMBL31339990 0.87 SORT1 (0.50) SORT1LCKBTKTRPV1
SCHEMBL31339954 0.84 VNN1 (0.45) KDM4EMAPTSORT1TRPV1
SCHEMBL31339994 0.84 TRPV1 (0.46) SORT1LCKTRPV1
SCHEMBL31339981 0.84 ALDH1A1 (0.43) ALDH1A1MEN1MAPTRECQLKMT2A
SCHEMBL31340005 0.81 TRPV1 (0.46) TRPV1
SCHEMBL31339987 0.81 TRPV1 (0.57) KDM4EMEN1MAPTKMT2ATSHR
SCHEMBL31340007 0.79 PTGS1 (0.54) SORT1BTKTRPV1
SCHEMBL31339962 0.79 LCK (0.59) LCKBTKTRPV1
SCHEMBL31339943 0.75 TRPV1 (0.48) ALDH1A1MEN1MAPTRECQLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124202-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF JILIN UNIVERSITY (CN) 2026-05-07 — — US disclosed
EP-4725485-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF Jilin University (CN) 2026-04-15 — — EP disclosed
CN-119285557-A CD97 and GSDME interaction inhibitor with anti-tumor activity and application thereof 吉林大学 2025-01-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124202-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF GZMB, CD74, GSDMD KDM4E 520/4885ALDH1A1 3962/4885ADCY8 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback